Asset Details
Do you wish to reserve the book?
Monitoring of Rivaroxaban Therapy in Hypercoagulable Dogs
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Monitoring of Rivaroxaban Therapy in Hypercoagulable Dogs
Do you wish to request the book?
Monitoring of Rivaroxaban Therapy in Hypercoagulable Dogs
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Monitoring of Rivaroxaban Therapy in Hypercoagulable Dogs
2025
Overview
Abstract
Background
Measurement of rivaroxaban efficacy using the rivaroxaban-specific anti-Xa assay (raXa) can be used for monitoring in veterinary medicine. Detection of rivaroxaban efficacy using other hemostatic tests would make monitoring timelier and more accessible.
Objectives
Compare results of raXa with prothrombin time (PT), activated partial thromboplastin time (aPTT), fibrinogen concentration, tissue factor (TF) and kaolin-activated thromboelastography (TEG), and thrombin generation (TG) in hypercoagulable dogs.
Animals
Twelve client-owned dogs, diagnosed with hypercoagulability or thromboembolic disease, and prescribed rivaroxaban, were recruited from a tertiary referral hospital from 2020 to 2022.
Methods
Prospective clinical trial. Jugular vein blood samples were collected before treatment, and 1 week and 1–3 months after initiation of rivaroxaban therapy. Hemostatic tests were performed at each visit (3 h after rivaroxaban dosing). TG curve parameters lag time, endogenous thrombin potential (ETP), peak, and time to peak (ttpeak) were assessed.
Results
There was a significant linear relationship between raXa and PT (r2 = 0.74, p < 0.001), ETP (r2 = 0.83, p < 0.001), lag time (r2 = 0.87, p < 0.001), peak (r2 = 0.86, p < 0.001), and ttpeak (r2 = 0.86, p < 0.001). There was a weak linear relationship between raXa and kaolin-activated TEG parameter reaction time (R) (r2 = 0.49, p = 0.026). There was no significant relationship between raXa and aPTT, fibrinogen concentration and the remainder of the TEG variables (p > 0.05).
Conclusion and Clinical Importance
PT and TG correlated with raXa. PT performed at a reference laboratory appeared to be a convenient method to monitor a small cohort of dogs receiving rivaroxaban therapy.
Publisher
Oxford University Press,John Wiley & Sons, Inc
Subject
/ Animals
/ blood
/ Blood Coagulation Tests - veterinary
/ Dogs
/ Factor Xa Inhibitors - therapeutic use
/ Female
/ Male
/ Partial Thromboplastin Time - veterinary
/ Plasma
/ Proteins
/ Prothrombin Time - veterinary
/ Rivaroxaban - therapeutic use
/ Thrombelastography - veterinary
/ thrombin
